.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Cantor Fitzgerald
McKesson
Citi
Daiichi Sankyo
Argus Health
Baxter
Queensland Health
US Army

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: RE41065

« Back to Dashboard

Which drugs does patent RE41065 protect, and when does it expire?


Patent RE41065 protects TARCEVA and is included in one NDA. There has been one Paragraph IV challenge on Tarceva.

Protection for TARCEVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-seven patent family members in forty-one countries.

Summary for Patent: RE41065

Title:Alkynl and azido-substituted 4-anilinoquinazolines
Abstract:The invention relates to compounds of the formula ##STR00001## and to pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.
Inventor(s): Schnur; Rodney Caughren (Noank, CT), Arnold; Lee Daniel (Mt. Sinai, NY)
Assignee: Pfizer, Inc. (New York, NY) OSI Pharmaceuticals, Inc. (Melville, NY)
Application Number:12/038,530
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-001Nov 18, 2004RXYesNo► Subscribe► Subscribe► SubscribeY
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-002Nov 18, 2004RXYesNo► Subscribe► Subscribe► SubscribeY
Osi PharmsTARCEVAerlotinib hydrochlorideTABLET;ORAL021743-003Nov 18, 2004RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: RE41065

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,747,498 Alkynyl and azido-substituted 4-anilinoquinazolines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE41065

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)735► Subscribe
African Regional IP Organization (ARIPO)9600788► Subscribe
Argentina002723► Subscribe
Austria205483► Subscribe
Austria446955► Subscribe
Australia3585499► Subscribe
Australia5040696► Subscribe
Australia703638► Subscribe
Australia778961► Subscribe
Australia7939101► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
Johnson and Johnson
Covington
Moodys
US Army
UBS
Teva
Harvard Business School
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot